SOURCE: Galapagos NV

April 18, 2007 02:00 ET

Galapagos announces agreement worth up to EUR 6.3 million with United States Environmental Protection Agency (EPA)

MECHELEN, BELGIUM -- (MARKET WIRE) -- April 18, 2007 --



Mechelen, Belgium; 18 April 2007 - Galapagos NV (Euronext & LSE: GLPG) announces today that its service division BioFocus DPI has entered into a multi year compound management agreement with the United States EPA. BioFocus DPI will provide chemical procurement and compound management services as part of the EPA's ToxCast™ Program (Prioritization of Environmentally Relevant Chemicals). The contract covers a period of up to five years and has a total value of up to EUR 6.3 million.

Under the agreement, which marks the first new compound management contract since the acquisition of the DPI assets in July 2006, BioFocus DPI will acquire, analyze, store, format and deliver specific compounds to a variety of sites selected by the EPA. The total size of the collection will be determined at the EPA's discretion.

"We are pleased that the EPA has selected BioFocus DPI to carry out the chemical procurement and management activities of the ToxCast™ program," stated Onno van de Stolpe, Chief Executive Officer of Galapagos. "The contract awarded by the EPA resulted from a competitive contracting process, which indicates that we are among the premier providers of compound management services based on both capabilities and price competitiveness."

"The EPA is an important new client to our compound management activities," stated Christopher Newton, Senior Vice President of BioFocus DPI. "We will apply many of the same skills and processes to this program that we have used and developed for the NIH's Roadmap Initiative."


About BioFocus DPI's compound management services

BioFocus DPI provides compound management services at its South San Francisco site. This facility is also home to the small molecule repository for the National Institutes of Health Roadmap Initiative. BioFocus DPI uses state-of-the-art equipment and sound compound handling techniques to ensure sample integrity. Furthermore, modern manufacturing practices ensure that screening samples are delivered in a timely manner across a wide range of formats for high throughput biological screening.

About Galapagos

Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA; London AiM: GLPG) is a drug discovery company with clinical and pre-clinical programs in bone and joint diseases, cachexia, and menopausal hot flashes. Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as chemogenomics and ADMET[1] database products to select targets and compounds. Galapagos currently employs 450 people and operates facilities in eight countries, with global headquarters in Mechelen, Belgium. More information about Galapagos and BioFocus DPI can be found at www.glpg.com and www.biofocusdpi.com.


CONTACT

Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com
This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

[1] ADMET is the acronym for Absorption, Distribution, Metabolism, Excretion, and Toxicity: meeting parameters against these five criteria is critical to the success of a pharmaceutical compound as a drug.





Copyright © Hugin ASA 2007. All rights reserved.

Contact Information